Protagonist Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2018; filed November 6, 2018. Protagonist is a clinical-stage biopharmaceutical company developing constrained peptide therapeutics. It has no approved products and has generated no product-sales revenue.
Business Context and Pipeline
- PTG-100: Oral alpha-4-beta-7 integrin antagonist for inflammatory bowel disease. The Phase 2 ulcerative colitis trial was discontinued in March 2018 after a futility analysis affected by unusually high placebo results. A subsequent independent blinded endoscopy re-read identified signals of clinical efficacy, and histopathology results supported further development.
- PTG-200: Oral IL-23 receptor antagonist licensed worldwide to Janssen for inflammatory bowel disease. Phase 1 was successfully completed, and the companies were working toward a U.S. IND and Phase 2 Crohn’s disease study.
- PTG-300: Injectable hepcidin mimetic for beta-thalassemia and other blood disorders. The Company planned to initiate a global Phase 2 beta-thalassemia study in the fourth quarter of 2018. PTG-300 received U.S. orphan drug and Fast Track designations and European orphan drug designation.
Financial Performance and Position
| Metric | Q3 2018 | Q3 2017 | 9M 2018 | 9M 2017 |
|---|---|---|---|---|
| License and collaboration revenue | $6.1 million | $8.8 million | $28.6 million | $8.8 million |
| Research and development expense | $12.1 million | $11.2 million | $45.2 million | $34.5 million |
| General and administrative expense | $3.4 million | $2.6 million | $10.2 million | $8.7 million |
| Loss from operations | $(9.4) million | $(5.0) million | $(26.9) million | $(34.4) million |
| Net loss | $(8.7) million | $(4.8) million | $(25.1) million | $(33.9) million |
| Net loss per share | $(0.38) | $(0.29) | $(1.15) | $(2.01) |
- Revenue was entirely license and collaboration revenue from Janssen and related services; the Company had no product revenue.
- Research and development expense increased 9% in the quarter and 31% year to date, primarily due to PTG-200 and PTG-300 clinical development. PTG-100 spending declined following the trial discontinuation.
- Interest income increased to $0.7 million in the quarter and $1.8 million year to date as a result of larger cash and investment balances.
- Cash, cash equivalents and available-for-sale securities totaled $138.5 million at September 30, 2018, compared with $155.5 million at December 31, 2017. Cash and cash equivalents were $87.4 million, and available-for-sale securities were $51.1 million.
- Net cash used in operating activities was $39.8 million for the first nine months of 2018, compared with $18.0 million provided in the prior-year period. Financing activities provided $23.6 million, including $21.7 million from the August private placement.
- The Company had no outstanding debt or credit facility. Total liabilities were $24.9 million, including $8.0 million of deferred revenue and $10.5 million of accrued expenses and other payables.
- Accumulated deficit was $126.6 million at September 30, 2018. No margins are presented because the Company is not generating product sales and remains loss-making.
Material Changes Versus the Prior Comparable Period
- Nine-month collaboration revenue increased $19.8 million, primarily because the Janssen agreement was effective for the full 2018 period and deferred revenue was recognized as performance obligations were satisfied.
- Third-quarter collaboration revenue declined $2.7 million, or 30%, because the amount of Janssen deferred revenue recognized based on proportional performance decreased.
- Operating loss increased $4.4 million in the third quarter because revenue declined while research and development and general and administrative expenses increased.
- Nine-month net loss improved by $8.8 million, mainly because collaboration revenue increased substantially more than operating expenses.
- On August 6, 2018, the Company sold 2.75 million shares at $8.00 per share for approximately $22.0 million of gross proceeds and issued warrants for 2.75 million additional shares. None of the warrants had been exercised at September 30, 2018. The warrants have exercise prices of $10.00 and $15.00 per share and expire in August 2023.
- The Company also sold 103,500 shares through its ATM facility for approximately $1.1 million of net proceeds; $48.8 million remained available under the facility.
Guidance, Outlook, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund operations and capital expenditures for at least 12 months from the filing date, but additional capital will be required to advance development and potentially commercialize the pipeline.
- The Company expects continuing losses and increased research and development expenses. It will likely seek additional equity, debt, collaboration or other financing, which may be unavailable or dilutive.
- Under the Janssen agreement, the Company may receive a $25.0 million payment upon IND filing, $125.0 million and $200.0 million opt-in payments tied to Phase 2 progress, and additional development, regulatory and sales milestones. The $25.0 million IND payment remained fully constrained at September 30, 2018, and no milestone or royalty revenue had been recognized.
- The Janssen agreement’s estimated transaction price increased to $56.4 million from $53.9 million at December 31, 2017, primarily due to higher estimated cost-sharing consideration. Revenue recognition depends on cost estimates and proportional performance, creating potential period-to-period volatility.
- Key risks include clinical failure or delays, regulatory uncertainty, manufacturing and CRO dependence, patient enrollment, competition, intellectual-property challenges, potential termination of the Janssen collaboration, and the need for substantial future financing.
- A patent infringement lawsuit concerning PTG-200 was dismissed without prejudice in February 2018. No amended complaint or appeal was filed, and the matter was described as concluded; the Company noted that future litigation could still arise if PTG-200 is commercialized.
- The Company awarded a $1.5 million Phase 2 NIH SBIR grant for PTG-300-related research, covering September 2018 through August 2020.
Investor Verification Checklist
- Verify the timing and probability of the PTG-200 IND filing, Phase 2 initiation and Janssen’s future opt-in decisions.
- Assess whether the revised PTG-100 data support a viable further-development strategy despite the discontinued Phase 2 trial and prior data-quality error.
- Track PTG-300 Phase 2 initiation, enrollment, safety and efficacy results.
- Reconcile quarterly cash burn with the stated liquidity runway and determine when additional financing may be required.
- Monitor Janssen-related deferred revenue, receivables, cost-sharing payments and the assumptions underlying proportional revenue recognition.
- Evaluate dilution from the August 2018 warrants, the ATM facility, stock options and restricted stock units.
- Review the continuing risks associated with third-party manufacturing, clinical vendors, intellectual property and potential termination of the Janssen agreement.